United States
Securities and Exchange Commission
Washington, DC 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: July 1, 2013
GeneLink, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
PA
|
00-30518
|
23-2795613
|
|
(State or other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
8250 Exchange Drive, Suite 120 Orlando FL 32835
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (800) 558-4363
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
- 1 -
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
(a) Resignation of Directors
On July 1, 2013, Dr. Douglas M. Boyle and Mr. James A. Monton resigned as directors of GeneLink, Inc. (the “Company”) Mr. Monton was the Chair of the Company’s Compensation Committee. In connection with their resignations, Dr. Boyle and Mr. Monton and the Company entered into mutual releases and the Company has agreed to allow all options held by Dr. Boyle and Mr. Monton to continue in effect through the remainder of their respective terms.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GeneLink, Inc. | |
| (Registrant) | |
|
By: /s/ Bernard L. Kasten, Jr. M.D.
|
|
|
|
Bernard L. Kasten, Jr. M.D.
|
|
|
CEO
|
Dated: July 5, 2013
- 2 -